

August 14, 2023

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Monday, August 14, 2023

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board Meeting of the Company held on Monday, August 14, 2023, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2023. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 14, 2023 are enclosed herewith.

The Board Meeting started at 10:30 a.m and concluded at 1:30 p.m.

Please take the same on record.

Thanking you,

For **AstraZeneca Pharma India Limited**


Manasa. R
Company Secretary



AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2023

SI No.	Particulars	Rs in lakhs except for earnings per share data			
		3 months ended 30/06/2023	Previous 3 months ended 31/03/2023	Corresponding 3 months ended in the previous year 30/06/2022	Year ended 31/03/2023
		Unaudited	Refer note 3	Unaudited	Audited
1	Income				
	a) Revenue from operations	29,546.68	28,470.35	23,233.20	100,297.08
	b) Other income	810.37	799.72	411.42	2,610.18
	Total income	30,357.05	29,270.07	23,644.62	102,907.26
2	Expenses				
	(a) Cost of materials consumed	1,907.76	2,161.98	1,589.15	8,437.84
	(b) Purchase of stock-in-trade	10,284.95	10,371.27	7,531.44	32,445.69
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,134.12)	(2,669.99)	(782.60)	(4,885.80)
	(d) Employee benefit expense	5,497.48	6,685.98	6,837.12	25,910.26
	(e) Depreciation expense	379.79	424.89	459.18	1,626.00
	(f) Allowance for expected credit loss (net)	(22.46)	41.29	99.00	167.03
	(g) Selling, marketing and distribution expense	2,126.61	1,378.72	1,073.50	5,974.17
	(h) Other expenses	4,161.91	4,516.24	4,089.31	15,735.38
	(i) Finance costs	15.35	8.80	18.62	63.32
	Total expenses	23,217.27	22,919.18	20,914.72	85,473.89
3	Profit before exceptional and extraordinary items and tax (1-2)	7,139.78	6,350.89	2,729.90	17,433.37
4	Exceptional items (Refer Note 4)	-	4,022.91	-	4,022.91
5	Profit before extraordinary items and tax (3-4)	7,139.78	2,327.98	2,729.90	13,410.46
6	Extraordinary items	-	-	-	-
7	Profit before tax (5-6)	7,139.78	2,327.98	2,729.90	13,410.46
8	Tax expense				
	- Current tax	1,746.70	838.18	767.51	3,830.25
	- Deferred tax charge/ (credit)	7.01	(237.32)	(52.87)	(349.04)
	Total tax expense	1,753.71	600.86	714.64	3,481.21
9	Profit after tax (7-8)	5,386.07	1,727.12	2,015.26	9,929.25
10	Other comprehensive income/(loss)				
	A. Items that will not be reclassified to profit or loss				
	Re-measurement gains/(losses) on post employment benefit obligations	60.82	(278.74)	(9.45)	(349.35)
	Income tax effect on above	(15.31)	70.15	2.38	87.92
	Other comprehensive income/ (loss), net of income tax	45.51	(208.59)	(7.07)	(261.43)
	Total comprehensive income for the period (9+10)	5,431.58	1,518.53	2,008.19	9,667.82
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00
12	Other Equity	-	-	-	58,368.83
13	Earnings per equity share of Rs 2/- each (basic and diluted)	21.54	6.91	8.06	39.72




Handwritten signature/initials

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,
Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2023

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 3 The figures for the quarter ended 31 March 2023 are the balancing figures between the audited figures in respect of the full financial year 31 March 2023 and the published unaudited year to date figures up to the third quarter of the respective financial year i.e., 31 December 2022 which were subjected to review by the statutory auditors.
- 4 Exceptional items for the quarter and year ended 31 March 2023 consists of separation cost amounting to Rs.1,910.32 and Voluntary Retirement Scheme expenses amounting to Rs.2,112.59.
- 5 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 14 August 2023. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2023.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjeev Kumar Panchal
Managing Director

Place: Bengaluru
Date: 14 August, 2023

